Dostarlimab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB15627 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | acetazolamide-responsive hereditary episodic ataxia | KG + DL |
| 2 | idiopathic anaphylaxis | KG + DL |
| 3 | ECHS1-related paroxysmal dyskinesia | KG + DL |
| 4 | hypereosinophilia of undetermined significance | KG + DL |
| 5 | alpha-gal syndrome | KG + DL |
| 6 | PRPS1 deficiency disorder | KG + DL |
| 7 | acquired adrenogenital syndrome | KG + DL |
| 8 | fatty acyl-CoA reductase 1 dysregulation | KG + DL |
| 9 | food protein-induced enterocolitis syndrome | KG + DL |
| 10 | TH-deficient infantile parkinsonism and motor delay | KG + DL |
| 11 | TH-deficient progressive infantile encephalopathy | KG + DL |
| 12 | SLC10A7-CDG | KG + DL |
| 13 | sudden arrhythmia death syndrome | KG + DL |
| 14 | tendinosis | KG + DL |
| 15 | adult-onset segmental dystonia | KG + DL |
| 16 | cardiocutaneous syndrome | KG + DL |
| 17 | neonatal diabetes, congenital sensorineural hearing loss and congenital cataracts | KG + DL |
| 18 | hearing loss, mixed conductive-sensorineural | KG + DL |
| 19 | methicillin-resistant staphylococcus aureus infectious disease | KG + DL |
| 20 | hearing loss with skin disease | KG + DL |
| 21 | norovirus infectious disease | KG + DL |
| 22 | self-limited familial and non-familial neonatal/infantile seizures | KG + DL |
| 23 | jaw fracture | KG + DL |
| 24 | cancer of long bone of upper limb | KG + DL |
| 25 | epilepsy of infancy with migrating focal seizures | KG + DL |
| 26 | cannabinoid hyperemesis syndrome | KG + DL |
| 27 | metastatic malignant neoplasm in the eye | KG + DL |
| 28 | non-neonatal early infantile epileptic encephalopathy | KG + DL |
| 29 | ACBD5 deficiency | KG + DL |
| 30 | Pericytoma with t(7;12) | KG + DL |
| 31 | acute flaccid myelitis | KG + DL |
| 32 | hallucinogen-persisting perception disorder | KG + DL |
| 33 | intrahepatic bile duct adenosquamous carcinoma | KG + DL |
| 34 | Uner Tan Syndrome | KG + DL |
| 35 | hyperkalemic renal tubular acidosis | KG + DL |
| 36 | AP-4 deficiency syndrome | KG + DL |
| 37 | combined ApoA-I and ApoC-III deficiency | KG + DL |
| 38 | A20 haploinsufficiency | KG + DL |
| 39 | drug pseudoallergy | KG + DL |
| 40 | long COVID-19 | KG + DL |
| 41 | colon serrated polyposis | KG + DL |
| 42 | vestibular ataxia | KG + DL |
| 43 | uterine ligament adenosarcoma | KG + DL |
| 44 | small intestinal bacterial overgrowth | KG + DL |
| 45 | skeletal fluorosis | KG + DL |
| 46 | refeeding syndrome | KG + DL |
| 47 | cerebral folate deficiency | KG + DL |
| 48 | phenytoin toxicity | KG + DL |
| 49 | structural epilepsy | KG + DL |
| 50 | idiopathic mast cell activation syndrome | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.